HIV感染者动脉粥样硬化性心血管疾病风险随时间的变化
研究利用TREAT Asia和澳大利亚HIV观察数据库数据,以D:A:D方程计算3368名成人HIV感染者启动抗逆转录病毒治疗时及治疗5年后的5年动脉粥样硬化性心血管疾病风险。结果显示风险从启动治疗时的0.84%升至治疗5年后的1.34%,且在不同HIV暴露亚群、种族/民族及基线CD4最低值亚组中上升速率相似。
要点
- HIV感染者启动ART时5年ASCVD风险为0.84%,治疗5年后升至1.34%。
- 不同HIV暴露方式、种族/民族及基线CD4最低值亚组的ASCVD风险上升速率相似。
- 作者认为需开发覆盖广泛HIV亚群有效的干预措施以应对ASCVD风险负担。
核心结论
- HIV感染者中ASCVD风险随ART治疗时间增加而上升,需开发在广泛HIV亚群中有效的干预措施。
研究设计与样本
- 研究使用TREAT Asia HIV观察数据库(TAHOD)和澳大利亚HIV观察数据库(AHOD)的数据。
- 纳入标准为年龄≥18岁、已启动ART、无既往ASCVD史且在ART启动后5年内有完整ASCVD危险因素数据。
- 共纳入3368名成人,其中TAHOD 3221人,AHOD 147人。
- 使用D:A:D方程计算5年ASCVD风险。
主要发现
- TAHOD参与者启动ART时中位年龄为36岁(IQR 31-43),AHOD参与者为42岁(IQR 35-50)。
- TAHOD参与者中男性占70.4%,AHOD参与者中男性占91.8%。
- 总体ASCVD风险从启动ART时的0.84%(95%CI 0.81%-0.87%)升至治疗5年后的1.34%(95%CI 1.29%-1.39%)。
- 调整传统及HIV相关ASCVD危险因素后,不同HIV暴露亚群(异性恋者、男男性行为者、注射吸毒者)、种族/民族(白种人和亚洲人)及启动ART时CD4最低值(<200和≥200 cells/mm3)亚组的ASCVD风险上升速率相似。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To describe changes in atherosclerotic cardiovascular disease (ASCVD) risk over time among people living with HIV (PLHIV). METHODS: We used data from the TREAT Asia HIV Observational Database (TAHOD) and the Australian HIV Observational Database (AHOD). Five-year ASCVD risk was calculated using the D:A:D equation. Individuals were eligible for inclusion if they were aged ≥18 years, had started ART, had no previous history of ASCVD and had complete ASCVD risk factor data available within the first 5 years of ART initiation. RESULTS: A total of 3368 adults contributed data, 3221 were from TAHOD and 147 were from AHOD. The median age at ART initiation was 36 [IQR 31-43] years for TAHOD participants, and 42 [IQR 35-50] years for AHOD participants. Most TAHOD (70.4%) and AHOD (91.8%) participants were male. Overall, ASCVD risk increased from 0.84% (95% CI 0.81%-0.87%) at ART initiation to 1.34% (95% CI 1.29%-1.39%) after 5 years on ART. After adjusting for traditional and HIV-associated ASCVD risk factors, ASCVD risk increased at a similar rate among sub-populations defined by HIV exposure (heterosexuals, men who have sex with men, people who inject drugs), race/ethnicity (Caucasian and Asian) and nadir CD4 at ART initiation (<200 and ≥200 cells/mm3). CONCLUSIONS: These findings emphasize the growing burden of ASCVD risk among PLHIV and the need to develop interventions that are effective across a broad range of HIV sub-populations.
引用
- Chen W, Petoumenos K, Somia A, et al. Changes in atherosclerotic cardiovascular disease risk over time among people living with HIV. J Antimicrob Chemother. 2024. PMID: 38416697. doi:10.1093/jac/dkae049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。